Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatic Encephalopathy: full-pipeline trial registry
5 of 13 indexed Hepatic Encephalopathy trials are currently recruiting.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 5 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Hepatic Encephalopathy: 13 US clinical trials tracked, 5 recruiting.
Hepatic Encephalopathy is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Bausch Health Americas, running 4 of these trials.
Enrollment posture brief
Registry condition hepatic-encephalopathy
OPEN 5 | RECR 38% | LATE 4 | EARLY 5 | RANK #1315 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Hepatic Encephalopathy lists 5 open slots (38% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatic Encephalopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatic Encephalopathy is recruiting below its size-band peers.
5 of 13 indexed trials (38.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hepatic Encephalopathy research.
Bausch Health Americas accounts for 4 of 13 trials (30.8%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatic Encephalopathy enrolment sits around 60 participants.
Median target enrolment is 60 among the 13 trials that report a genuine target (sentinel values excluded). 7 of those (53.8%) plan for fewer than 100 participants.
-
Hepatic Encephalopathy research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
TReatment for ImmUne Mediated PathopHysiology
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04862221
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
The Cleveland Clinic
NCT04096014
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT06052176
Affect of Melatonin on Sleep and Cognition in Cirrhosis
Weill Medical College of Cornell University
NCT07046429
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
Mayo Clinic
NCT06425380
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Bausch Health Americas
NCT05071716
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Bausch Health Americas
NCT05297448
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
Massachusetts General Hospital
NCT03420482
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
Bausch Health Americas
NCT00686920
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
Bausch Health Americas
NCT01842581
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Amgen
NCT00999167
FMT in Cirrhosis and Hepatic Encephalopathy
VA Office of Research and Development
NCT03796598
Rifaximin in Minimal Hepatic Encephalopathy
Hunter Holmes Mcguire Veteran Affairs Medical Center
NCT00533910
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatic Encephalopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatic Encephalopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatic Encephalopathy page
13 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Hepatic Encephalopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bausch Health Americas sponsors the most Hepatic Encephalopathy trials on record, review their full trial history before evaluating a specific study. See Bausch Health Americas's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatic Encephalopathy condition card totals 13 registered trials; most-linked intervention Rifaximin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.